A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Elevate-HF
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)
2 other identifiers
interventional
6,950
24 countries
364
Brief Summary
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Aug 2026
Typical duration for phase_3
364 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 3, 2026
CompletedFirst Posted
Study publicly available on registry
August 12, 2026
CompletedStudy Start
First participant enrolled
August 28, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
September 3, 2029
Study Completion
Last participant's last visit for all outcomes
September 3, 2029
August 12, 2026
August 1, 2026
3 years
August 3, 2026
August 7, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To evaluate the effect of elecoglipron compared with placebo in reducing the risk of CV death or HHF/urgent HF visit
Time to first event of the composite of: CV death HHF Urgent HF visit
Up to 42 months
Secondary Outcomes (3)
To evaluate the effect of elecoglipron compared with placebo in reducing the rate of HF events (HHF or urgent HF visit)
Up to 42 months
To evaluate the effect of elecoglipron compared to placebo on improving patient-reported outcomes using a questionnaire
Baseline and 52 weeks
To evaluate the effect of elecoglipron compared with placebo in reducing the risk of the 4-point composite of all-cause death, HHF, MI, or stroke
Up to 42 months
Study Arms (2)
Elecoglipron
EXPERIMENTALElecoglipron tablet once daily
Placebo
ACTIVE COMPARATORPlacebo matching Elecoglipron tablet once daily
Interventions
Eligibility Criteria
You may qualify if:
- Left ventricular ejection fraction (LVEF) of \> 40% within 12 months prior to screening.
- Structural heart disease evidence.
- HF diagnosed with New York Heart Association (NYHA) Class II-IV at the time of screening.
You may not qualify if:
- BMI \<25 kg/m² at screening.
- History of type 1 diabetes.
- HbA1c ≥10% at screening.
- Currently receiving or anticipated to receive therapeutic intervention for diabetic retinopathy and/or macular edema.
- more than 1 episode of severe hypoglycemic event within 180 days prior to screening, or hypoglycemia unawareness/poor recognition.
- On a prespecified renal replacement therapy, or eGFR below a prespecified threshold at screening
- Major cardiac surgery, coronary revascularization, valvular repair/replacement, AF/AFL ablation, CRT implantation, or ICD without CRT within 90 days prior to screening, or planned after randomization.
- Heart failure due to infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, genetic hypertrophic cardiomyopathy (including obstructive), or arrhythmogenic right ventricular cardiomyopathy/dysplasia.
- Clinically significant upper GI condition affecting gastric emptying, drug absorption, or safety/tolerability interpretation; chronic use of drugs directly affecting GI motility; severe disease or prior surgery.
- History of acute or chronic pancreatitis.
- History/ family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2, or basal calcitonin ≥35 ng/L at screening.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (366)
Research Site
Fairhope, Alabama, 36532, United States
Research Site
Beverly Hills, California, 90211, United States
Research Site
Huntington Beach, California, 92647, United States
Research Site
Huntington Park, California, 90255, United States
Research Site
Loma Linda, California, 92350, United States
Research Site
Lomita, California, 90717, United States
Research Site
Northridge, California, 91324, United States
Research Site
Tarzana, California, 91356, United States
Research Site
New Haven, Connecticut, 06519, United States
Research Site
Hialeah, Florida, 33012, United States
Research Site
Jacksonville, Florida, 32209, United States
Research Site
Lakeland, Florida, 33813, United States
Research Site
Miami, Florida, 33125, United States
Research Site
Miami, Florida, 33144, United States
Research Site
Atlanta, Georgia, 30303, United States
Research Site
Columbus, Georgia, 31904, United States
Research Site
Tucker, Georgia, 30084, United States
Research Site
Champaign, Illinois, 61822, United States
Research Site
Park Ridge, Illinois, 60068, United States
Research Site
Schaumburg, Illinois, 60173, United States
Research Site
Indianapolis, Indiana, 46254, United States
Research Site
Waterloo, Iowa, 50701, United States
Research Site
Bossier City, Louisiana, 71111, United States
Research Site
Covington, Louisiana, 70433, United States
Research Site
Lafayette, Louisiana, 70503, United States
Research Site
New Orleans, Louisiana, 70121, United States
Research Site
Shreveport, Louisiana, 71105, United States
Research Site
Baltimore, Maryland, 21229, United States
Research Site
Lanham, Maryland, 20706, United States
Research Site
Oxon Hill, Maryland, 20745, United States
Research Site
Boston, Massachusetts, 02114, United States
Research Site
Boston, Massachusetts, 02118, United States
Research Site
New Bedford, Massachusetts, 02740, United States
Research Site
Worcester, Massachusetts, 01655, United States
Research Site
Flint, Michigan, 48503, United States
Research Site
Southfield, Michigan, 48076, United States
Research Site
Kansas City, Missouri, 64111, United States
Research Site
St Louis, Missouri, 63136, United States
Research Site
Millville, New Jersey, 08332, United States
Research Site
Trenton, New Jersey, 08690, United States
Research Site
Buffalo, New York, 14215, United States
Research Site
New York, New York, 10001, United States
Research Site
The Bronx, New York, 10451, United States
Research Site
The Bronx, New York, 10455, United States
Research Site
Chapel Hill, North Carolina, 27599, United States
Research Site
Durham, North Carolina, 27710, United States
Research Site
Greensboro, North Carolina, 27410, United States
Research Site
Statesville, North Carolina, 28625, United States
Research Site
Wilmington, North Carolina, 28401, United States
Research Site
Fargo, North Dakota, 58104, United States
Research Site
Grand Forks, North Dakota, 58201, United States
Research Site
Columbus, Ohio, 43228, United States
Research Site
Dayton, Ohio, 45435, United States
Research Site
Maumee, Ohio, 43537, United States
Research Site
Oklahoma City, Oklahoma, 73134, United States
Research Site
Philadelphia, Pennsylvania, 19104, United States
Research Site
Philadelphia, Pennsylvania, 19107, United States
Research Site
Yardley, Pennsylvania, 19067, United States
Research Site
DeSoto, Texas, 75115, United States
Research Site
El Paso, Texas, 79905, United States
Research Site
Houston, Texas, 77025, United States
Research Site
Humble, Texas, 77338, United States
Research Site
Lancaster, Texas, 75216, United States
Research Site
Plano, Texas, 75093, United States
Research Site
San Antonio, Texas, 78231, United States
Research Site
Victoria, Texas, 77901, United States
Research Site
Burlington, Vermont, 05401, United States
Research Site
Arlington, Virginia, 22205, United States
Research Site
Redmond, Washington, 98052, United States
Research Site
Buenos Aires, C1425AGC, Argentina
Research Site
CABA, C1061, Argentina
Research Site
Córdoba, 5000, Argentina
Research Site
Córdoba, X5003DCE, Argentina
Research Site
Granadero Baigorria, S2152BOF, Argentina
Research Site
Lanus, B1824KAJ, Argentina
Research Site
Mar del Plata, B7600GNY, Argentina
Research Site
Mendoza, 5500, Argentina
Research Site
Rosario, S2000PBJ, Argentina
Research Site
San Nicolás, B2900ACL, Argentina
Research Site
Santa Fe, S3000FWO, Argentina
Research Site
Blacktown, 2148, Australia
Research Site
Rockhampton, 4700, Australia
Research Site
Bad Ischl, 4820, Austria
Research Site
Feldkirch, 6800, Austria
Research Site
Graz, 8020, Austria
Research Site
Graz, 8036, Austria
Research Site
Innsbruck, 6020, Austria
Research Site
Klagenfurt, 9020, Austria
Research Site
Linz, 4021, Austria
Research Site
Saint Stefan/Stainz, 8511, Austria
Research Site
Sankt Pölten, 3100, Austria
Research Site
Vienna, 1090, Austria
Research Site
Vienna, 1100, Austria
Research Site
Vienna, 1160, Austria
Research Site
Vienna, 1210, Austria
Research Site
Wels, 4600, Austria
Research Site
Aracaju, 49015-380, Brazil
Research Site
Belém, 66073-005, Brazil
Research Site
Bragança Paulista, 12916-542, Brazil
Research Site
Brasília, 70390-700, Brazil
Research Site
Campinas, 13060-080, Brazil
Research Site
Curitiba, 80230-130, Brazil
Research Site
Joinville, 89204-251, Brazil
Research Site
Natal, 59020-035, Brazil
Research Site
Porto Alegre, 90630-165, Brazil
Research Site
Porto Alegre, 91350-280, Brazil
Research Site
Ribeirão Preto, 14051-140, Brazil
Research Site
Rio Branco, 69915-030, Brazil
Research Site
Rio de Janeiro, 22270-060, Brazil
Research Site
São Paulo, 04012-180, Brazil
Research Site
Barrie, Ontario, L4M 6M2, Canada
Research Site
Hamilton, Ontario, L8L 5G4, Canada
Research Site
Kingston, Ontario, K7M 7E4, Canada
Research Site
London, Ontario, N6A 5W9, Canada
Research Site
Newmarket, Ontario, L3Y 2P6, Canada
Research Site
North York, Ontario, M6B 3H7, Canada
Research Site
Oakville, Ontario, L6K 3W7, Canada
Research Site
Stoney Creek, Ontario, L8J 3W2, Canada
Research Site
Thunder Bay, Ontario, P7B 5N3, Canada
Research Site
Toronto, Ontario, M6G 1M2, Canada
Research Site
Toronto, Ontario, M6N 1B5, Canada
Research Site
Montreal, Quebec, H4A 3J1, Canada
Research Site
Luoyang, 471001, China
Research Site
Tianjin, 300050, China
Research Site
Wuhan, 430000, China
Research Site
Zhangjiakou, 075061, China
Research Site
Benešov, 256 01, Czechia
Research Site
Boskovice, 680 01, Czechia
Research Site
Brno, 60200, Czechia
Research Site
Broumov, 55001, Czechia
Research Site
Chlumec nad Cidlinou, 503 51, Czechia
Research Site
Česká Lípa, 470 77, Czechia
Research Site
Český Krumlov, 381 01, Czechia
Research Site
Jaroměř, 551 01, Czechia
Research Site
Klatovy, 339 01, Czechia
Research Site
Louny, 440 01, Czechia
Research Site
Prague, 130 00, Czechia
Research Site
Prague, 150 00, Czechia
Research Site
Prague, 198 00, Czechia
Research Site
Teplice, 415 01, Czechia
Research Site
Bad Oldesloe, 23843, Germany
Research Site
Bamberg, 96049, Germany
Research Site
Berlin, 13187, Germany
Research Site
Berlin, 13405, Germany
Research Site
Berlin, 13509, Germany
Research Site
Bielefeld, 33604, Germany
Research Site
Bochum, 44789, Germany
Research Site
Bremen, 28277, Germany
Research Site
Chemnitz, 09116, Germany
Research Site
Cologne, 50733, Germany
Research Site
Dresden, 1307, Germany
Research Site
Elsterwerda, 04910, Germany
Research Site
Erlangen, 91504, Germany
Research Site
Essen, 45147, Germany
Research Site
Freiburg im Breisgau, 79106, Germany
Research Site
Gera, 07548, Germany
Research Site
Hamburg, 20099, Germany
Research Site
Hamburg, 21075, Germany
Research Site
Hamburg, 22459, Germany
Research Site
Hamburg, 22559, Germany
Research Site
Heidelberg, 69120, Germany
Research Site
Homburg, 66424, Germany
Research Site
Jena, 07747, Germany
Research Site
Kaiserslautern, 67655, Germany
Research Site
Karlsbad, 76307, Germany
Research Site
Kiel, 24105, Germany
Research Site
Ludwigshafen, 67063, Germany
Research Site
Ludwigshafen am Rhein, 67071, Germany
Research Site
Lüneburg, 21339, Germany
Research Site
Magdeburg, 39120, Germany
Research Site
Mainz, 55122, Germany
Research Site
Mainz, 55131, Germany
Research Site
Markkleeberg, 04416, Germany
Research Site
Mühldorf A. Inn, 84453, Germany
Research Site
Neuruppin, 16816, Germany
Research Site
Nuremberg, 90402, Germany
Research Site
Obertshausen, 63179, Germany
Research Site
Paderborn, 33098, Germany
Research Site
Papenburg, 26871, Germany
Research Site
Stuttgart, 70199, Germany
Research Site
Trier, 54292, Germany
Research Site
Tübingen, 72076, Germany
Research Site
Ulm, 89077, Germany
Research Site
Athens, 11521, Greece
Research Site
Athens, 11526, Greece
Research Site
Athens, 11527, Greece
Research Site
Athens, 11528, Greece
Research Site
Athens, 15123, Greece
Research Site
Dragana, 68100, Greece
Research Site
Heraklion, 71409, Greece
Research Site
Heraklio, 71110, Greece
Research Site
Thessaloniki, 54636, Greece
Research Site
Voula, 16673, Greece
Research Site
Budapest, 1122, Hungary
Research Site
Ancona, 60100, Italy
Research Site
Bergamo, 24127, Italy
Research Site
Brescia, 25123, Italy
Research Site
Milan, 20132, Italy
Research Site
Pavia, 27100, Italy
Research Site
Perugia, 06132, Italy
Research Site
Riccione, 47838, Italy
Research Site
Salerno, 84131, Italy
Research Site
Sesto San Giovanni, 20099, Italy
Research Site
Vizzolo Predabissi, 20070, Italy
Research Site
Aomori, 030-8553, Japan
Research Site
Fukui-shi, 910-8526, Japan
Research Site
Higashiibaraki-gun, 311-3193, Japan
Research Site
Kanazawa, 920-8650, Japan
Research Site
Kasugai-shi, 486-8510, Japan
Research Site
Kyoto, 604-8845, Japan
Research Site
Kyoto, 605-0981, Japan
Research Site
Matsusaka-shi, 515-8557, Japan
Research Site
Minatoku, 108-0073, Japan
Research Site
Mito, 311-4198, Japan
Research Site
Nagoya, 466-8560, Japan
Research Site
Osaka, 558-8558, Japan
Research Site
Ōmihachiman, 523-0082, Japan
Research Site
Sapporo, 003-0026, Japan
Research Site
Sendai, 981-3133, Japan
Research Site
Takatsuki-shi, 569-8686, Japan
Research Site
Tokushima, 770-8503, Japan
Research Site
Toshima-ku, 171-0014, Japan
Research Site
Urasoe-Shi, 901-2102, Japan
Research Site
Uruma, 904-2293, Japan
Research Site
Wakayama, 640-8158, Japan
Research Site
Alor Star, 05460, Malaysia
Research Site
Cheras, 56000, Malaysia
Research Site
Kuala Lumpur, 50400, Malaysia
Research Site
Kuala Lumpur, 50586, Malaysia
Research Site
Kuala Lumpur, 59100, Malaysia
Research Site
Kuala Terengganu, 20400, Malaysia
Research Site
Kuantan, 25100, Malaysia
Research Site
Kuching, 93586, Malaysia
Research Site
Miri, 98000, Malaysia
Research Site
Sungai Buloh, 47000, Malaysia
Research Site
Alkmaar, 1815 JD, Netherlands
Research Site
Almere Stad, 1315 RA, Netherlands
Research Site
Amstelveen, 1186 AM, Netherlands
Research Site
Doetinchem, 7009 BL, Netherlands
Research Site
Leeuwarden, 8934 AD, Netherlands
Research Site
Rotterdam, 3015, Netherlands
Research Site
Sneek, 8601 ZR, Netherlands
Research Site
The Hague, 2545 AA, Netherlands
Research Site
Tilburg, 5042 AD, Netherlands
Research Site
Zutphens, 7207 AE, Netherlands
Research Site
Zwolle, 8025 AB, Netherlands
Research Site
Bialystok, 15-375, Poland
Research Site
Bialystok, 15-481, Poland
Research Site
Częstochowa, 42-217, Poland
Research Site
Gdynia, 81-157, Poland
Research Site
Gdynia, 81-338, Poland
Research Site
Katowice, 40-600, Poland
Research Site
Katowice, 40-635, Poland
Research Site
Krakow, 30-082, Poland
Research Site
Krakow, 31-271, Poland
Research Site
Poznan, 61-848, Poland
Research Site
Przemyśl, 37-700, Poland
Research Site
Radzionków, 41-922, Poland
Research Site
Skórzewo, 60-185, Poland
Research Site
Szczecin, 71-526, Poland
Research Site
Torun, 87-100, Poland
Research Site
Warsaw, 02-758, Poland
Research Site
Warsaw, 04-628, Poland
Research Site
Wroclaw, 50-981, Poland
Research Site
Baia Mare, 430124, Romania
Research Site
Brasov, 500102, Romania
Research Site
Bucharest, 031441, Romania
Research Site
Bucharest, 050098, Romania
Research Site
Bucharest, 050659, Romania
Research Site
Craiova, 200505, Romania
Research Site
Satu Mare, 440055, Romania
Research Site
Timișoara, 300002, Romania
Research Site
Timișoara, 300024, Romania
Research Site
Timișoara, 300362, Romania
Research Site
Bratislava, 82107, Slovakia
Research Site
Bratislava, 83101, Slovakia
Research Site
Brezno, 977 01, Slovakia
Research Site
Košice, 04001, Slovakia
Research Site
Košice, 04022, Slovakia
Research Site
Lučenec, 984 01, Slovakia
Research Site
Lučenec, 98401, Slovakia
Research Site
Nitra, 949 11, Slovakia
Research Site
Prešov, 08001, Slovakia
Research Site
Svidník, 08901, Slovakia
Research Site
Šahy, 93601, Slovakia
Research Site
Barcelona, 08003, Spain
Research Site
Barcelona, 08035, Spain
Research Site
Barcelona, 08036, Spain
Research Site
Jaén, 23007, Spain
Research Site
Madrid, 28034, Spain
Research Site
Madrid, 28041, Spain
Research Site
Murcia, 30120, Spain
Research Site
Salamanca, 37007, Spain
Research Site
Sanlúcar de Barrameda (Cádiz), 11540, Spain
Research Site
Seville, 41013, Spain
Research Site
Valencia, 46010, Spain
Research Site
Valencia, 46014, Spain
Research Site
Valencia, 46026, Spain
Research Site
Villamartín, 11650, Spain
Research Site
Gothenburg, 416 85, Sweden
Research Site
Jönköping, 553 05, Sweden
Research Site
Karlstad, 651 85, Sweden
Research Site
Lund, 222 21, Sweden
Research Site
Mölndal, 431 80, Sweden
Research Site
Örebro, 701 85, Sweden
Research Site
Stockholm, 112 81, Sweden
Research Site
Stockholm, 113 61, Sweden
Research Site
Stockholm, 118 83, Sweden
Research Site
Stockholm, 171 64, Sweden
Research Site
Uppsala, 751 85, Sweden
Research Site
Kaohsiung City, 80756, Taiwan
Research Site
New Taipei City, 231, Taiwan
Research Site
New Taipei City, Taiwan
Research Site
Taichung, 40201, Taiwan
Research Site
Taichung, 40705, Taiwan
Research Site
Taichung, 433004, Taiwan
Research Site
Taipei, 10002, Taiwan
Research Site
Taipei, 10449, Taiwan
Research Site
Taipei, 110, Taiwan
Research Site
Taipei, 11101, Taiwan
Research Site
Taipei, 11217, Taiwan
Research Site
Taoyuan, 333, Taiwan
Research Site
Yilan, 260, Taiwan
Research Site
Bangkok, 10300, Thailand
Research Site
Bangkok, 10330, Thailand
Research Site
Bangkok, 10700, Thailand
Research Site
Changwat Sara Buri, 18000, Thailand
Research Site
Chiang Mai, 50200, Thailand
Research Site
Hat Yai, 90110, Thailand
Research Site
Khlong Luang, 12120, Thailand
Research Site
Khon Kaen, 40002, Thailand
Research Site
Phitsanulok, 65000, Thailand
Research Site
Ratchaburi, 70000, Thailand
Research Site
Kyiv, 01601, Ukraine
Research Site
Kyiv, 02002, Ukraine
Research Site
Kyiv, 03037, Ukraine
Research Site
Kyiv, 03049, Ukraine
Research Site
Kyiv, 03057, Ukraine
Research Site
Kyiv, 03151, Ukraine
Research Site
Kyiv, 04050, Ukraine
Research Site
Kyiv, 04114, Ukraine
Research Site
Kyiv, 04210, Ukraine
Research Site
Lviv, 79016, Ukraine
Research Site
Uzhhorod, 88002, Ukraine
Research Site
Uzhhorod, 88014, Ukraine
Research Site
Ashton-under-Lyne, OL6 6EW, United Kingdom
Research Site
Basildon, SS16 5NL, United Kingdom
Research Site
Belfast, BT16 1RH, United Kingdom
Research Site
Birmingham, B75 7RR, United Kingdom
Research Site
Brighton, BN2 5BE, United Kingdom
Research Site
Bristol, BS34 5TF, United Kingdom
Research Site
Clydebank, G81 4DY, United Kingdom
Research Site
Dundee, DD1 9SY, United Kingdom
Research Site
Glasgow, G51 4TF, United Kingdom
Research Site
Kings Lynn, PE30 4ET, United Kingdom
Research Site
Leeds, LS1 3EX, United Kingdom
Research Site
London, EC1M 6BQ, United Kingdom
Research Site
Sandbach, CW11 1EQ, United Kingdom
Research Site
Southampton, SO303JB, United Kingdom
Research Site
Can Tho, 900000, Vietnam
Research Site
Hanoi, 100000, Vietnam
Research Site
Hà Nội, 100000, Vietnam
Research Site
Ho Chi Minh City, 700000, Vietnam
Research Site
Ho Chi Minh City, 70000, Vietnam
Research Site
Hochiminh City, 700000, Vietnam
Research Site
Hochiminh, 700000, Vietnam
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
AstraZeneca Clinical Study Information Center
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Placebo controlled
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 3, 2026
First Posted
August 12, 2026
Study Start (Estimated)
August 28, 2026
Primary Completion (Estimated)
September 3, 2029
Study Completion (Estimated)
September 3, 2029
Last Updated
August 12, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.